Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis.

ABSTRACT:

Background

Recent clinical trials demonstrated longer survival in extended small cell lung cancer (SCLC) patients treated with immunotherapy in addition to chemotherapy. However, the magnitude of benefit is modest and the impact in real-world setting has to be fully established.

Methods

We collected clinical data and radiological imaging of patients affected by extended or relapsing SCLC and consecutively treated according to clinical practice between 2016 and 2023. As primary end-point, we compared pre-defined outcome indicators before and after the introduction of chemo-immunotherapy (May 2020): 6-month and 12-month progression free survival (PFS) rate, 12-month and 18-month overall survival (OS). Among those who were treated after May 2020, patients who did not receive im

SUBMITTER: Bonanno L 

PROVIDER: S-EPMC10845350 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature